Total Payments
$383,523
2024 Payments
$76,528
Companies
44
Transactions
1,053
Medicare Patients
5,092
Medicare Billing
$435,719
Payment Breakdown by Category
Other$240,738 (62.8%)
Research$73,965 (19.3%)
Food & Beverage$27,548 (7.2%)
Consulting$21,885 (5.7%)
Travel$19,387 (5.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $207,058 | 83 | 54.0% |
| Unspecified | $73,965 | 43 | 19.3% |
| Food and Beverage | $27,548 | 816 | 7.2% |
| Consulting Fee | $21,885 | 10 | 5.7% |
| Travel and Lodging | $19,387 | 81 | 5.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $18,200 | 7 | 4.7% |
| Honoraria | $13,480 | 11 | 3.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,000 | 2 | 0.5% |
Payments by Type
General
$309,559
1,010 transactions
Research
$73,965
43 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $198,859 | 302 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $94,530 | 121 | $0 (2024) |
| Madrigal Pharmaceuticals | $27,002 | 27 | $0 (2024) |
| ABBVIE INC. | $18,615 | 261 | $0 (2024) |
| Intercept Pharma Europe Ltd. | $8,272 | 3 | $0 (2024) |
| Allergan Inc. | $8,248 | 3 | $0 (2017) |
| Merck Sharp & Dohme LLC | $7,150 | 12 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $5,379 | 10 | $0 (2024) |
| Cook Incorporated | $3,002 | 1 | $0 (2019) |
| Olympus Corporation of the Americas | $2,475 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $76,528 | 244 | Gilead Sciences, Inc. ($34,795) |
| 2023 | $19,280 | 155 | Gilead Sciences, Inc. ($12,819) |
| 2022 | $19,653 | 104 | Gilead Sciences, Inc. ($14,246) |
| 2021 | $43,856 | 88 | Intercept Pharmaceuticals, Inc. ($21,912) |
| 2020 | $39,089 | 66 | Intercept Pharmaceuticals, Inc. ($22,809) |
| 2019 | $46,531 | 95 | Gilead Sciences, Inc. ($28,448) |
| 2018 | $48,893 | 122 | Intercept Pharmaceuticals, Inc. ($24,492) |
| 2017 | $89,694 | 179 | Gilead Sciences Inc ($53,985) |
All Payment Transactions
1,053 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.63 | General |
| 12/18/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,763.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/18/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $11.24 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,673.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $124.76 | General |
| Category: LIVER DISEASE | ||||||
| 12/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/10/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.31 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Gastroenterology | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.36 | General |
| 12/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $0.31 | General |
| 11/25/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $30.13 | General |
| Category: Immunology | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: Immunology | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $8.45 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $114.96 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $31.26 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $24.52 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $11.68 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: Immunology | ||||||
| 11/19/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug), Linzess | Food and Beverage | Cash or cash equivalent | $18.43 | General |
| Category: GI | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) | INTERCEPT PHARMACEUTICALS, INC. | $20,875 | 16 |
| 1009742 | Intercept Pharmaceuticals, Inc. | $20,484 | 8 |
| 1011866 | INTERCEPT PHARMACEUTICALS, INC. | $12,782 | 10 |
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | Intercept Pharma Europe Ltd. | $8,272 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. | Allergan Inc. | $8,248 | 3 |
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | INTERCEPT PHARMACEUTICALS, INC. | $2,276 | 2 |
| 1011866 | Intercept Pharmaceuticals, Inc. | $1,028 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 948 | 1,018 | $549,480 | $99,988 |
| 2022 | 10 | 1,204 | 1,267 | $524,105 | $98,412 |
| 2021 | 15 | 1,547 | 1,664 | $657,165 | $129,675 |
| 2020 | 12 | 1,393 | 1,478 | $522,038 | $107,643 |
Total Patients
5,092
Total Services
5,427
Medicare Billing
$435,719
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 129 | 132 | $171,600 | $27,916 | 16.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 226 | 274 | $61,650 | $25,201 | 40.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 118 | 119 | $119,000 | $10,928 | 9.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 131 | 132 | $105,600 | $10,885 | 10.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 36 | 36 | $33,660 | $6,526 | 19.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 79 | 93 | $9,300 | $6,049 | 65.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 96 | 98 | $14,700 | $5,608 | 38.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $6,875 | $3,370 | 49.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 22 | 22 | $20,570 | $3,180 | 15.5% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 86 | 87 | $6,525 | $324.09 | 5.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 123 | 123 | $159,900 | $25,001 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 199 | 219 | $49,275 | $19,730 | 40.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 244 | 279 | $27,900 | $16,597 | 59.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 53 | 53 | $49,555 | $9,957 | 20.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 107 | 112 | $89,600 | $8,817 | 9.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 98 | 98 | $98,000 | $7,085 | 7.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 66 | 66 | $9,900 | $4,442 | 44.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 33 | 33 | $9,075 | $3,445 | 38.0% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 128 | 128 | $19,200 | $2,738 | 14.3% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2022 | 153 | 156 | $11,700 | $600.16 | 5.1% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 137 | 138 | $179,400 | $29,151 | 16.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 330 | 406 | $40,725 | $27,483 | 67.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 184 | 212 | $47,700 | $19,122 | 40.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 66 | 66 | $61,575 | $12,779 | 20.8% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 148 | 150 | $120,135 | $11,803 | 9.8% |
About Dr. Thomas Sepe, MD
Dr. Thomas Sepe, MD is a Gastroenterology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508937889.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Sepe, MD has received a total of $383,523 in payments from pharmaceutical and medical device companies, with $76,528 received in 2024. These payments were reported across 1,053 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($207,058).
As a Medicare-enrolled provider, Sepe has provided services to 5,092 Medicare beneficiaries, totaling 5,427 services with total Medicare billing of $435,719. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Providence, RI
- Active Since 11/10/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1508937889
Products in Payments
- Epclusa (Drug) $77,550
- Vemlidy (Drug) $50,401
- OCALIVA (Drug) $37,359
- REZDIFFRA (Drug) $26,632
- OCA (Drug) $16,804
- Mavyret (Drug) $14,863
- Livdelzi (Drug) $11,318
- Vosevi (Drug) $10,927
- ZEPATIER (Drug) $7,115
- IQIRVO (Drug) $5,288
- Olympus Tissue Acquisition Devices (Device) $2,475
- XIFAXAN (Drug) $1,135
- FibroScan (Device) $1,000
- ZEPOSIA (Drug) $991.49
- SKYRIZI (Biological) $847.62
- CC-90001 (Drug) $760.85
- Humira (Biological) $691.91
- RINVOQ (Biological) $617.29
- STELARA (Biological) $549.65
- XELJANZ (Drug) $540.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Providence
Paul Akerman, Md, MD
Gastroenterology — Payments: $163,964
Gastroenterology $163,964
Sean Fine, M.d, M.D
Gastroenterology — Payments: $63,236
Gastroenterology $63,236
Dr. Alan Epstein, M.d, M.D
Gastroenterology — Payments: $59,290
Gastroenterology $59,290
Samir Shah, M.d, M.D
Gastroenterology — Payments: $45,756
Gastroenterology $45,756
Lisa Mueller, Md, MD
Gastroenterology — Payments: $22,692
Gastroenterology $22,692
Eric Newton, Md, MD
Gastroenterology — Payments: $20,736
Gastroenterology $20,736